ClinConnect ClinConnect Logo
Search / Trial NCT06885619

Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction Though Plasma Multiomics Analysis.

Launched by BEIJING ANZHEN HOSPITAL · Mar 14, 2025

Trial Information

Current as of April 23, 2025

Active, not recruiting

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age ≥ 18 years.
  • 2. Diagnosis of AMI (STEMI or NSTEMI) confirmed by clinical criteria, electrocardiogram (ECG), and cardiac biomarkers (e.g., troponin).
  • 3. Willingness to provide informed consent.
  • Exclusion Criteria:
  • 1. Prior surgery or trauma.
  • 2. Renal failure with glomerular filtration \<30 ml/min.

Trial Officials

Xu Wang, Dr.

Principal Investigator

Beijing Anzhen hospital, Capital Mediacl University.

Tanxi Cai, Dr.

Study Director

Institute of Biophysics, Chinese Academy of Sciences

About Beijing Anzhen Hospital

Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported